These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17646286)

  • 21. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
    Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
    Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic cancer genome sequencing and the contribution of germline variants.
    Kilpivaara O; Aaltonen LA
    Science; 2013 Mar; 339(6127):1559-62. PubMed ID: 23539595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A probabilistic approach for automated discovery of perturbed genes using expression data from microarray or RNA-Seq.
    Sundaramurthy G; Eghbalnia HR
    Comput Biol Med; 2015 Dec; 67():29-40. PubMed ID: 26492320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional analysis of p53 tumor suppressor in yeast.
    Smardová J; Smarda J; Koptíková J
    Differentiation; 2005 Jul; 73(6):261-77. PubMed ID: 16138827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer.
    Chava S; Mohan V; Shetty PJ; Manolla ML; Vaidya S; Khan IA; Waseem GL; Boddala P; Ahuja YR; Hasan Q
    Dis Esophagus; 2012 Jan; 25(1):81-7. PubMed ID: 21668571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dual role of mutant p53 protein in chemosensitivity of human cancers.
    Mueller H; Eppenberger U
    Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate prediction of enzyme mutant activity based on a multibody statistical potential.
    Masso M; Vaisman II
    Bioinformatics; 2007 Dec; 23(23):3155-61. PubMed ID: 17977887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
    Leroy B; Anderson M; Soussi T
    Hum Mutat; 2014 Jun; 35(6):672-88. PubMed ID: 24665023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of relevant features from amino acids enables development of robust classifiers.
    Das Roy R; Dash D
    Amino Acids; 2014 May; 46(5):1343-51. PubMed ID: 24604165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of the p53 gene.
    Sidransky D; Hollstein M
    Annu Rev Med; 1996; 47():285-301. PubMed ID: 8712782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations.
    Nikolova PV; Wong KB; DeDecker B; Henckel J; Fersht AR
    EMBO J; 2000 Feb; 19(3):370-8. PubMed ID: 10654936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germ-line-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions.
    Aurelio ON; Cajot JF; Hua ML; Khwaja Z; Stanbridge EJ
    Cancer Res; 1998 May; 58(10):2190-5. PubMed ID: 9605765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer molecular pattern discovery by subspace consensus kernel classification.
    Han X
    Comput Syst Bioinformatics Conf; 2007; 6():55-65. PubMed ID: 17951812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational biases associated with potential iron-binding DNA motifs in rodent lacI and human p53 mutational databases.
    Sonntag DM; de Boer J; Medvedovic M; Baxter CS; LeMasters G; Talaska G
    Mutat Res; 2004 Jun; 550(1-2):73-88. PubMed ID: 15135642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
    Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
    Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 Mutants Access Epigenetic Pathways to Promote Tumor Growth.
    Cancer Discov; 2015 Nov; 5(11):OF2. PubMed ID: 26424413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Machine learning-based investigation of the cancer protein secretory pathway.
    Saghaleyni R; Sheikh Muhammad A; Bangalore P; Nielsen J; Robinson JL
    PLoS Comput Biol; 2021 Apr; 17(4):e1008898. PubMed ID: 33819271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.